Australian Clinical Labs Ltd ( (AU:ACL) ) has shared an update.
Australian Clinical Labs Limited announced the cessation of Michael Thomas Alscher as a director, effective April 30, 2025. Alscher, who held interests in 280,502 ordinary shares through XYZ Services Pty Limited as trustee for the 3C Trust, will no longer be part of the company’s board. This change in directorship might impact the company’s governance and strategic direction, potentially affecting stakeholders and market perception.
More about Australian Clinical Labs Ltd
Australian Clinical Labs Limited (ACL) operates in the healthcare industry, focusing on providing pathology services. The company is involved in delivering diagnostic services and laboratory testing, which are crucial for medical professionals and patients in Australia.
YTD Price Performance: -10.88%
Average Trading Volume: 985,163
Technical Sentiment Signal: Buy
Current Market Cap: A$601.7M
Learn more about ACL stock on TipRanks’ Stock Analysis page.